Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase II study of irinotecan in patients with advanced colorectal cancer previously treated with 5-fluorouracil.
Méndez M, Salut A, García-Girón C, Navalon M, Diz P, García López MJ, España P, de la Torre A, Martínez del Prado P, Duarte I, Pujol E, Arizcun A, Cruz JJ. Méndez M, et al. Among authors: salut a. Clin Colorectal Cancer. 2003 Nov;3(3):174-9. doi: 10.3816/ccc.2003.n.023. Clin Colorectal Cancer. 2003. PMID: 14706177 Clinical Trial.
A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer.
Gravalos C, Salut A, García-Girón C, García-Carbonero R, León AI, Sevilla I, Maurel J, Esteban B, García-Rico E, Murias A, Cortés-Funes H. Gravalos C, et al. Among authors: salut a. Clin Transl Oncol. 2012 Aug;14(8):606-12. doi: 10.1007/s12094-012-0843-x. Epub 2012 Jul 19. Clin Transl Oncol. 2012. PMID: 22855138 Free PMC article. Clinical Trial.
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
Saigi E, Salut A, Campos JM, Losa F, Manzano H, Batiste-Alentorn E, Acusa A, Vélez de Mendizabal E, Guasch I, Antón I; ACROSS Cooperative Group. Saigi E, et al. Among authors: salut a. Anticancer Drugs. 2004 Oct;15(9):835-41. doi: 10.1097/00001813-200410000-00003. Anticancer Drugs. 2004. PMID: 15457123 Clinical Trial.